Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Journal of cellular physiology - 1 Jul 2009

Harada Yuka, Harada Hironori

Abstract excerpt

AML1/RUNX1 point mutations have been identified in myelodysplastic syndrome (MDS) and MDS-related acute myeloid leukemia (AML), or MDS/AML, and are distributed throughout the full length of AML1/RUNX1. Gene mutation is proposed to be one of the disease-defining genetic abnormalities of MDS/AML. Most of the mutants lose trans-activation potential, which leads to a loss of normal function indicating that AML1/RUNX1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Cell Transformation, Neoplastic
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Hematopoietic Stem Cells

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Point Mutation

Source

Identifiers

PMID: 19334039
DOI: 10.1002/jcp.21769

Genes

RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.PMID 19334039Read ↗

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.Semantic proximity Read ↗

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.Semantic proximity Read ↗

Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.Semantic proximity Read ↗

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutationsSemantic proximity Read ↗

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemiaSemantic proximity Read ↗

RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes.Semantic proximity Read ↗

New mechanisms of AML1 gene alteration in hematological malignancies.Semantic proximity Read ↗

SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.Semantic proximity Read ↗

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasmsSemantic proximity Read ↗

Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

AML1 mutations induced MDS and MDS/AML in a mouse BMT model.Semantic proximity Read ↗

AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.